176 related articles for article (PubMed ID: 22581215)
1. A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type.
Otte A; Göhring G; Steinemann D; Schlegelberger B; Groos S; Länger F; Kreipe HH; Schambach A; Neumann T; Hillemanns P; Park-Simon TW; Hass R
Int J Oncol; 2012 Aug; 41(2):765-75. PubMed ID: 22581215
[TBL] [Abstract][Full Text] [Related]
2. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcemic-type of small cell carcinoma of the ovary: characterization of a new tumor line.
Walt H; Hornung R; Fink D; Dobler-Girdziunaite D; Stallmach T; Spycher MA; Maly F; Haller U; Bürki N
Anticancer Res; 2001; 21(5):3253-9. PubMed ID: 11848480
[TBL] [Abstract][Full Text] [Related]
5. Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.
Harrison ML; Hoskins P; du Bois A; Quinn M; Rustin GJ; Ledermann JA; Baron-Hay S; Friedlander ML
Gynecol Oncol; 2006 Feb; 100(2):233-8. PubMed ID: 16321429
[TBL] [Abstract][Full Text] [Related]
6. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
[TBL] [Abstract][Full Text] [Related]
7. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
[TBL] [Abstract][Full Text] [Related]
8. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
Callegaro-Filho D; Gershenson DM; Nick AM; Munsell MF; Ramirez PT; Eifel PJ; Euscher ED; Marques RM; Nicolau SM; Schmeler KM
Gynecol Oncol; 2016 Jan; 140(1):53-7. PubMed ID: 26546963
[TBL] [Abstract][Full Text] [Related]
9. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
10. Interference of Ca²⁺ with the proliferation of SCCOHT-1 and ovarian adenocarcinoma cells.
Otte A; Rauprich F; von der Ohe J; Hillemanns P; Hass R
Int J Oncol; 2014 Sep; 45(3):1151-8. PubMed ID: 24969518
[TBL] [Abstract][Full Text] [Related]
11. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond
Auguste A; Blanc-Durand F; Deloger M; Le Formal A; Bareja R; Wilkes DC; Richon C; Brunn B; Caron O; Devouassoux-Shisheboran M; Gouy S; Morice P; Bentivegna E; Sboner A; Elemento O; Rubin MA; Pautier P; Genestie C; Cyrta J; Leary A
Cells; 2020 Jun; 9(6):. PubMed ID: 32575483
[TBL] [Abstract][Full Text] [Related]
12. Small cell carcinoma of the ovary of hypercalcemic type: a case report.
McDonald JM; Karabakhtsian RG; Pierce HH; Iocono JA; Desimone CP; Bayliff SL; Ueland FR
J Pediatr Surg; 2012 Mar; 47(3):588-92. PubMed ID: 22424359
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model.
Otte A; Rauprich F; Hillemanns P; Park-Simon TW; von der Ohe J; Hass R
Orphanet J Rare Dis; 2014 Aug; 9():126. PubMed ID: 25103190
[TBL] [Abstract][Full Text] [Related]
14. [Small cell carcinoma of ovary, hypercalcemic type: analysis of clinicopathologic characteristics and the diagnostic utility of loss expression of SMARCA4 protein].
Wang L; Tan C; Tu X; Zhang Y; Li X; Chang B
Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):859-63. PubMed ID: 26888501
[TBL] [Abstract][Full Text] [Related]
15. Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary): A Review with Recent Developments on Pathogenesis.
Witkowski L; Goudie C; Foulkes WD; McCluggage WG
Surg Pathol Clin; 2016 Jun; 9(2):215-26. PubMed ID: 27241105
[TBL] [Abstract][Full Text] [Related]
16. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
Fahiminiya S; Witkowski L; Nadaf J; Carrot-Zhang J; Goudie C; Hasselblatt M; Johann P; Kool M; Lee RS; Gayden T; Roberts CW; Biegel JA; Jabado N; Majewski J; Foulkes WD
Oncotarget; 2016 Jan; 7(2):1732-40. PubMed ID: 26646792
[TBL] [Abstract][Full Text] [Related]
17. SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment.
Otte A; Yang Y; von der Ohe J; Melzer C; Hillemanns P; Feuerhake F; Hass R
Int J Oncol; 2016 Dec; 49(6):2453-2463. PubMed ID: 27748897
[TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
[TBL] [Abstract][Full Text] [Related]
19. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG
Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304
[TBL] [Abstract][Full Text] [Related]
20. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.
Chiriva-Internati M; Grizzi F; Weidanz JA; Ferrari R; Yuefei Y; Velez B; Shearer MH; Lowe DB; Frezza EE; Cobos E; Kast WM; Kennedy RC
J Immunol Methods; 2007 Apr; 321(1-2):86-93. PubMed ID: 17336323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
